Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 106
Filter
2.
Emerg Microbes Infect ; 9(1): 2728-2731, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33258732

ABSTRACT

A 40-year-old female was found to have strongly neutralizing SARS-CoV-2 breastmilk IgA and IgG antibodies reactive against multiple SARS-CoV-2 antigens at 2.5 months after documented infection with SARS-CoV-2. At 6.5 months following the infection, she remained positive for breastmilk and serum SARS-CoV-2 neutralizing antibodies. Holder breast milk pasteurization did not diminish SARS-CoV-2 antibody titres but it reduced its neutralizing capacity, while serum heat inactivation had no negative effect on SARS-CoV-2 serum antibody levels and neutralizing capacity. Current data on SARS-CoV-2 and breastmilk are reviewed.


Subject(s)
Antibodies, Viral/analysis , Antigens, Viral/immunology , Coronavirus Nucleocapsid Proteins/immunology , Milk, Human/immunology , Spike Glycoprotein, Coronavirus/immunology , Adult , Female , Humans , Protein Binding , Protein Domains
3.
Gene Ther ; 23(10): 753-759, 2016 10.
Article in English | MEDLINE | ID: mdl-27416077

ABSTRACT

Immune responses against multiple epitopes are required for the prevention of hepatitis C virus (HCV) infection, and the progression to phase I trials of candidates may be guided by comparative immunogenicity studies in non-human primates. Four vectors, DNA, SFV, human serotype 5 adenovirus (HuAd5) and Modified Vaccinia Ankara (MVA) poxvirus, all expressing hepatitis C virus Core, E1, E2 and NS3, were combined in three prime-boost regimen, and their ability to elicit immune responses against HCV antigens in rhesus macaques was explored and compared. All combinations induced specific T-cell immune responses, including high IFN-γ production. The group immunized with the SFV+MVA regimen elicited higher E2-specific responses as compared with the two other modalities, while animals receiving HuAd5 injections elicited lower IL-4 responses as compared with those receiving MVA. The IFN-γ responses to NS3 were remarkably similar between groups. Only the adenovirus induced envelope-specific antibody responses, but these failed to show neutralizing activity. Therefore, the two novel regimens failed to induce superior responses as compared with already existing HCV vaccine candidates. Differences were found in response to envelope proteins, but the relevance of these remain uncertain given the surprisingly poor correlation with immunogenicity data in chimpanzees, underlining the difficulty to predict efficacy from immunology studies.


Subject(s)
B-Lymphocytes/immunology , Epitopes/genetics , Hepacivirus/immunology , T-Lymphocytes/immunology , Viral Hepatitis Vaccines/immunology , Adenoviridae/genetics , Animals , Cell Line , Cricetinae , Epitopes/immunology , Genetic Vectors/genetics , Immunogenicity, Vaccine , Interferon-gamma/blood , Interleukin-4/blood , Macaca mulatta , Male , Vaccinia virus/genetics , Viral Hepatitis Vaccines/genetics
4.
J Viral Hepat ; 21(3): 223-8, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24438684

ABSTRACT

Canine hepacivirus (CHV) has recently been identified in liver and respiratory tract samples from dogs, and comparative phylogenetic analysis has confirmed it to be the closest genetic relative of hepatitis C virus (HCV) described to date. CHV offers great potential as a model system for HCV, but only if the underlying processes of infection and pathogenesis are similar for both viruses. However, it is not yet clear if CHV is hepatotrophic. Canine chronic hepatitis (CH) is a common and usually idiopathic disease that shares similar histological features to that of HCV infection of humans. To date, no study has attempted to determine whether CHV is involved in the aetiology of liver disease in dogs. We employed two nested PCR assays, using primers targeting regions of the helicase domain of CHV NS3, to identify viral nucleic acids in liver samples from 100 dogs with CH of unknown cause in the UK. We also used a sensitive luciferase immunoprecipitation system (LIPS) assay to screen serum samples from these dogs for the presence of anti-CHV antibodies. Surprisingly, there was no evidence of exposure to, or a carrier state of, CHV in this large cohort, suggesting that the virus is not associated with CH in UK dogs. Future work, including transmission studies, is required to understand the pathogenesis of CHV in canids before it can be proposed as a surrogate model for HCV-induced liver disease in man.


Subject(s)
Dog Diseases/etiology , Hepacivirus/genetics , Hepatitis C, Chronic/veterinary , Liver Diseases/veterinary , Animals , Dog Diseases/diagnosis , Dogs , Hepacivirus/immunology , Hepatitis C Antibodies/blood , Hepatitis C Antibodies/immunology , RNA, Viral/genetics , Viral Nonstructural Proteins/immunology
5.
J Med Primatol ; 37(4): 196-201, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18194222

ABSTRACT

BACKGROUND AND METHODS: To investigate the seroprevalence of polyomavirus infections in macaques, we analyzed 1579 sera from nine different species for antibodies cross-reactive with simian virus 40 (SV40) in an enzyme-linked immunosorbent assay. Most samples were collected from captive animals, but we also investigated a colony of free-ranging Barbary macaques (Macaca sylvanus). RESULTS: High seropositive rates were found in rhesus macaques (Macaca mulatta; 74.7%), cynomolgus macaques (Macaca fascicularis; 44.8%) and Tonkean macaques (Macaca tonkeana; 41.7%), especially in animals imported from China. Low rates were measured in cynomolgus macaques from Mauritius (8.8%), and in Barbary macaques (1.4%). Seropositivity was age-dependent increasing to >70% in animals of 5 years and older. CONCLUSIONS: High seroprevalence rates were found in different species of macaques, dependent on their origin. Very low infection rates found in Barbary macaques and cynomolgus macaques from Mauritius suggest that these animals in the wild are not commonly infected by SV40-like viruses.


Subject(s)
Animals, Wild , Animals, Zoo , Antibodies, Viral/blood , Macaca/virology , Polyomavirus Infections/veterinary , Animals , Capsid Proteins/immunology , Mauritius/epidemiology , Polyomavirus Infections/epidemiology , Seroepidemiologic Studies
6.
J Med Virol ; 79(5): 474-82, 2007 May.
Article in English | MEDLINE | ID: mdl-17385685

ABSTRACT

The rapidly spreading HIV epidemic requires a vaccine that elicits potent mucosal immunity to halt or slow transmission. Induction of these responses will depend on the use of appropriate adjuvants and targeting of the mucosal immune system. Previously, immune stimulating complexes (ISCOM) have shown great potency as adjuvant in the induction of mucosal responses in mice and systemic responses in non-human primates. In this study, HIV formulated in PR8-Flu ISCOM adjuvant was applied to immunize rhesus macaques against HIV; targeting the mucosa either via intranasal (IN) application or via targeted lymph node immunization (TLNI). While, strong systemic, HIV specific, cytokine, lymphoproliferative, and antibody responses were induced via the TLNI route, the IN application generated only low responses. Furthermore, all four animals immunized via TLNI developed vaginal IgA antibodies against gp120. In conclusion, in contrast to what has been demonstrated in mice, the IN application of PR8-Flu ISCOM did not induce strong immune responses in rhesus macaques unlike those immunized by the TLNI route.


Subject(s)
AIDS Vaccines/administration & dosage , Adjuvants, Immunologic/administration & dosage , HIV Antibodies/analysis , HIV Infections/immunology , HIV-1/immunology , ISCOMs/administration & dosage , Immunization , AIDS Vaccines/immunology , Administration, Intranasal , Animals , Antibody Specificity , Female , HIV Core Protein p24/administration & dosage , HIV Core Protein p24/immunology , HIV Envelope Protein gp120/administration & dosage , HIV Envelope Protein gp120/immunology , Humans , Immunization Schedule , Immunoglobulin A/analysis , Injections, Intralymphatic , Macaca mulatta , Vaccines, Subunit/administration & dosage , Vagina/immunology
7.
J Intern Med ; 260(5): 399-408, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17040245

ABSTRACT

Public awareness of the human health risks of zoonotic infections has grown in recent years. Currently, concern of H5N1 flu transmission from migratory bird populations has increased with foci of fatal human cases. This comes on the heels of other major zoonotic viral epidemics in the last decade. These include other acute emerging or re-emerging viral diseases such as severe acute respiratory syndrome (SARS), West-Nile virus, Ebola virus, monkeypox, as well as the more inapparent insidious slow viral and prion diseases. Virus infections with zoonotic potential can become serious killers once they are able to establish the necessary adaptations for efficient human-to-human transmission under circumstances sufficient to reach epidemic proportions. The monitoring and early diagnosis of these potential risks are overlapping frontiers of human and veterinary medicine. Here, current viral zoonotics and evolving threats are reviewed.


Subject(s)
Communicable Diseases, Emerging , RNA Virus Infections , Zoonoses , Animals , Birds , Communicable Diseases, Emerging/diagnosis , Communicable Diseases, Emerging/epidemiology , Communicable Diseases, Emerging/transmission , Disease Outbreaks , Early Diagnosis , Humans , Influenza A Virus, H5N1 Subtype/pathogenicity , Influenza in Birds/transmission , Influenza, Human/diagnosis , Influenza, Human/epidemiology , Influenza, Human/transmission , RNA Virus Infections/diagnosis , RNA Virus Infections/epidemiology , RNA Virus Infections/transmission , Severe acute respiratory syndrome-related coronavirus/pathogenicity , Severe Acute Respiratory Syndrome/diagnosis , Severe Acute Respiratory Syndrome/epidemiology , Severe Acute Respiratory Syndrome/transmission , Zoonoses/epidemiology , Zoonoses/transmission
8.
J Med Virol ; 75(2): 313-20, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15602728

ABSTRACT

Noroviruses, with Norwalk virus as the prototype strain, are the most common cause of viral gastroenteritis in people of all ages. Limited information on the immunology of Norovirus infections has been obtained by studies both in the natural setting and in experimentally infected volunteers. Interpretation of these studies is difficult due to the lack of information on the history of Norovirus exposure and the cross-reactivity of antibodies. An animal model for Norovirus infections would be important to study the immune response, e.g., for vaccine assessment. In the present study the susceptibility of common marmosets, cotton top tamarins, cynomolgus, and rhesus macaques to Norovirus infection was tested. Following oral inoculation, low level replication may have occurred in common marmosets and cotton top tamarins but not in cynomolgus macaques, based on short-term viral shedding; neither clinical symptoms nor antibody responses were observed in these species. In contrast, rhesus macaques were found susceptible to Norwalk virus infection as one animal shed virus for a longer period of time and developed Norwalk virus specific IgM and IgG responses. Further research on Norovirus susceptibility in rhesus macaques may yield an animal model to study the immune response and pathogenesis after Norovirus infection.


Subject(s)
Caliciviridae Infections/immunology , Norovirus/isolation & purification , Norovirus/pathogenicity , ABO Blood-Group System , Animals , Antibodies, Viral/blood , Ape Diseases/epidemiology , Blood Group Antigens , Caliciviridae Infections/blood , Caliciviridae Infections/epidemiology , Caliciviridae Infections/veterinary , Callithrix/immunology , Callithrix/virology , Disease Models, Animal , Feces/virology , Macaca fascicularis/immunology , Macaca fascicularis/virology , Macaca mulatta/immunology , Macaca mulatta/virology , Monkey Diseases/epidemiology , Norovirus/immunology , Pan troglodytes/virology , RNA, Viral/isolation & purification , Saguinus/immunology , Saguinus/virology , Virus Shedding/genetics
9.
Vaccine ; 22(23-24): 2974-84, 2004 Aug 13.
Article in English | MEDLINE | ID: mdl-15356916

ABSTRACT

Cell-surface CCR5 is a major coreceptor with CD4 glycoprotein, mediating cellular entry of CCR5 strains of HIV-1 or SIV. We targeted the SIV CCR5 coreceptor in a combined CCR5-SIV antigen immunization strategy. Rhesus macaques were immunized i.m. with the 70 kDa heat shock protein (HSP70) covalently linked to the CCR5 peptides, SIV gpl20 and p27. Intravenous challenge with SIV mac 8980 prevented SIV infection or decreased the viral load with the CCR5-SIV combined vaccine. CC chemokines and antibodies which block and downmodulateCCR5 were induced, as well as immune responses to the subunit SIV antigens. This novel vaccination strategy complements cognate immunity to SIV with innate immunity to the CCR5 coreceptor of SIV.


Subject(s)
Receptors, CCR5/immunology , SAIDS Vaccines/therapeutic use , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Acquired Immunodeficiency Syndrome/prevention & control , Amino Acid Sequence , Animals , Antibodies, Viral/analysis , Antibodies, Viral/biosynthesis , Antigens, Surface/immunology , Antigens, Viral/immunology , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Gene Products, rex/genetics , Gene Products, rex/immunology , HSP70 Heat-Shock Proteins/metabolism , Immunization Schedule , Immunoglobulin A/analysis , Immunoglobulin A/biosynthesis , Immunoglobulin G/analysis , Immunoglobulin G/biosynthesis , Kinetics , Macaca mulatta , Membrane Glycoproteins/genetics , Membrane Glycoproteins/immunology , Molecular Sequence Data , Mycobacterium tuberculosis/immunology , T-Lymphocytes/immunology , Viral Envelope Proteins/genetics , Viral Envelope Proteins/immunology
10.
J Gen Virol ; 85(Pt 8): 2407-2419, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15269383

ABSTRACT

The immunogenicity and protective efficacy of a DNA and recombinant modified vaccinia Ankara (MVA) vaccine administered by two different routes were investigated. DNA expressing HIV-1 IIIB env, gag, RT, rev, tat and nef, and MVA expressing HIV-1 IIIB nef, tat and rev and simian immunodeficiency virus (SIV) macJ5 gag/pol and vaccinia HIV-1 env, were used as immunogens. Four cynomolgus macaques received DNA intramuscularly (i.m.) at month 0 and intrarectally (i.r.) and intra-orally (i.o.) at 2 months, followed by MVA i.m. at 4 months and i.r. and i.o. at 8 months. Another group of four monkeys received the same immunogens but only i.m. Overall, stronger cellular immune responses measured by ELISPOT and T-cell proliferation assay were detected in the group primed i.m. and boosted mucosally. Following homologous intravenous simian-human immunodeficiency virus (SHIV) challenge, one of eight vaccinated animals was completely protected. This monkey, immunized i.m. and i.r.+i.o., exhibited the highest levels of HIV Env, Nef and Tat antibodies, high HIV Tat cytotoxic T-lymphocyte activity and T-lymphocyte proliferative responses to HIV Env. Four weeks post-challenge none of the monkeys immunized i.m. and i.r.+i.o., and only two out of four animals immunized i.m., demonstrated detectable plasma viral RNA levels. In contrast, all eight control animals had demonstrable plasma viral RNA levels 4 weeks post-challenge. Thus, stronger cellular immune responses and reduction of challenge virus burden were demonstrated in animals immunized i.m. as well as mucosally, compared with animals immunized i.m. only. The breadth and magnitude of the induced immune responses correlated with protective efficacy.


Subject(s)
SAIDS Vaccines/immunology , Simian Acquired Immunodeficiency Syndrome/immunology , Vaccines, DNA/immunology , Vaccinia virus/immunology , Animals , HIV Antibodies/blood , Immunization , Interferon-gamma/biosynthesis , Macaca fascicularis , SAIDS Vaccines/administration & dosage , Simian Acquired Immunodeficiency Syndrome/prevention & control , T-Lymphocytes, Cytotoxic/immunology , Vaccines, DNA/administration & dosage , Viral Load
11.
J Virol ; 78(1): 187-96, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14671100

ABSTRACT

Prophylactic hepatitis C virus (HCV) vaccine trials with human volunteers are pending. There is an important need for immunological end points which correlate with vaccine efficacy and which do not involve invasive procedures, such as liver biopsies. By using a multicomponent DNA priming-protein boosting vaccine strategy, naïve chimpanzees were immunized against HCV structural proteins (core, E1, and E2) as well as a nonstructural (NS3) protein. Following immunization, exposure to the heterologous HCV 1b J4 subtype resulted in a peak of plasma viremia which was lower in both immunized animals. Compared to the naïve infection control and nine additional historical controls which became chronic, vaccinee 2 (Vac2) rapidly resolved the infection, while the other (Vac1) clearly controlled HCV infection. Immunization induced antibodies, peptide-specific gamma interferon (IFN-gamma), protein-specific lymphoproliferative responses, IFN-gamma, interleukin-2 (IL-2), and IL-4 T-helper responses in both vaccinees. However, the specificities were markedly different: Vac2 developed responses which were lower in magnitude than those of Vac1 but which were biased towards Th1-type cytokine responses for E1 and NS3. This proof-of-principle study in chimpanzees revealed that immunization with a combination of nonstructural and structural antigens elicited T-cell responses associated with an alteration of the course of infection. Our findings provide data to support the concept that the quality of the response to conserved epitopes and the specific nature of the peripheral T-helper immune response are likely pivotal factors influencing the control and clearance of HCV infection.


Subject(s)
Hepacivirus/immunology , Hepatitis C, Chronic/prevention & control , Th1 Cells/immunology , Th2 Cells/immunology , Viral Hepatitis Vaccines/immunology , Animals , Cytokines/biosynthesis , Hepacivirus/pathogenicity , Hepatitis C Antibodies/blood , Hepatitis C Antigens/immunology , Hepatitis C, Chronic/immunology , Humans , Immunization , Lymphocyte Activation/immunology , Pan troglodytes , Viral Core Proteins/immunology , Viral Hepatitis Vaccines/administration & dosage , Viral Nonstructural Proteins/immunology
12.
Gene Ther ; 10(10): 890-901, 2003 May.
Article in English | MEDLINE | ID: mdl-12732874

ABSTRACT

Before autoimmune diseases in humans can be treated with gene therapy, the safety and efficacy of the used vectors must be tested in valid experimental models. Monkeys, such as the rhesus macaque or the common marmoset, provide such models. This publication reviews the state of the art in monkey models for rheumatoid arthritis and multiple sclerosis and the (few) gene therapy experiments that have been performed in these models.


Subject(s)
Autoimmune Diseases/therapy , Genetic Therapy/methods , Models, Animal , Primates , Animals , Arthritis/immunology , Arthritis/therapy , Autoimmune Diseases/immunology , Encephalomyelitis, Autoimmune, Experimental/immunology , Encephalomyelitis, Autoimmune, Experimental/therapy , Genetic Vectors/administration & dosage , Haplorhini , Humans , Interleukin-4/genetics , Interleukin-4/immunology , Multiple Sclerosis/immunology , Multiple Sclerosis/therapy
13.
J Gen Virol ; 84(Pt 3): 615-620, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12604813

ABSTRACT

A retrospective study spanning 20 years was undertaken to investigate the prevalence and modes of transmission of a simian T-cell lymphotropic virus (STLV) in a closed breeding colony of chimpanzees. Of the 197 animals tested, 22 had antibodies that were cross-reactive with human T-cell lymphotropic virus type-1 (HTLV-I) antigens. The specificity of the antibody response was confirmed by Western blot analysis and the presence of a persistent virus infection was established by PCR analysis of DNA from peripheral blood mononuclear cells. Sequence analysis revealed that the virus infecting these chimpanzees was not HTLV-I but STLV(cpz), a virus that naturally infects chimpanzees. The limited number of transmission events suggested that management practices of social housing of family units away from troops of mature males might have prevented the majority of cases of transmission. Evidence for transmission by blood-to-blood contact was documented clearly in at least one instance. In contrast, transmission from infected mother to child was not observed, suggesting that this is not a common route of transmission for STLV in this species, which is in contrast to HTLV-1 in humans.


Subject(s)
Ape Diseases/transmission , Deltaretrovirus Infections/veterinary , Pan troglodytes , Simian T-lymphotropic virus 1/genetics , Animals , Antibodies, Viral/blood , Ape Diseases/blood , Ape Diseases/virology , Deltaretrovirus Infections/transmission , Disease Transmission, Infectious , Female , Human T-lymphotropic virus 1/immunology , Leukocytes, Mononuclear/virology , Male , Molecular Sequence Data , Phylogeny , Polymerase Chain Reaction , Prevalence , Retrospective Studies , Sex Factors , Simian T-lymphotropic virus 1/chemistry , Simian T-lymphotropic virus 1/classification , Viral Envelope Proteins/genetics
14.
AIDS ; 15(18): 2359-69, 2001 Dec 07.
Article in English | MEDLINE | ID: mdl-11740186

ABSTRACT

OBJECTIVE: HIV-1 infection in humans has been reported to lead to a shift in the cytokine balance, with a relative decrease in T helper 1 type cytokines, especially IL-2. On the basis of the expression of CD45RA, in combination with homing markers CD62L or alpha4beta7, T helper cells can be sub-divided into naive, activated naive, central memory and effector memory cells as well as gut-homing subpopulations. In addition, each subset may have the potential to express distinct cytokines. At present it is unclear whether the changes in cytokine expression observed in HIV-1-infected individuals are secondary to changes within the composition of CD4 T cell subsets or are caused by changes in cytokine expression within each subset. MATERIALS AND METHODS: A new technique was developed to detect cytokine expression in phorbol 12-myristate 13-acetate/ionomycin-activated CD62L and alpha4beta7-expressing CD4 T cell subsets, using the protease inhibitor KD-IX-73-4. RESULTS: In SIV-infected macaques that develop AIDS a marked decrease in IL-2 expression was found within central, effector, or gut-homing memory cell subsets, whereas the expression of IL-2 in naive T cell subsets remained unaffected. This reduced IL-2 expression by memory cells and not a loss of the frequency of CD4 memory cells accounted for the reduced expression of IL-2 by CD4 T cells during SIV infection. CONCLUSION: As defined by the cell surface markers utilized, it appears that progression to AIDS is associated with functional impairment of memory cells, but not changes in lymphocyte circulation patterns.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Immunologic Memory/immunology , Interleukin-2/metabolism , Simian Acquired Immunodeficiency Syndrome/physiopathology , Simian Immunodeficiency Virus/immunology , Animals , Cytokines/metabolism , Disease Models, Animal , Disease Progression , Flow Cytometry/methods , Humans , Macaca mulatta , Simian Acquired Immunodeficiency Syndrome/immunology , T-Lymphocyte Subsets/immunology , T-Lymphocytes, Helper-Inducer/immunology
15.
Immunol Lett ; 79(1-2): 101-7, 2001 Nov 01.
Article in English | MEDLINE | ID: mdl-11595296

ABSTRACT

Dendritic cells (DC) have been implicated in the pathogenesis of both human and simian immunodeficiency viruses (HIV and SIV, respectively). The DC-specific HIV-1 trans-receptor DC-SIGN is thought to be essential for viral dissemination by DC. Abundant expression in lymphoid tissues also implies a function for DC-SIGN in chronic HIV-1 infections, in facilitating persistent infection of T cells. We have therefore isolated the rhesus macaque and chimpanzee homologues of DC-SIGN to investigate their function in a primate model. Both rhesus macaque and chimpanzee DC-SIGN are highly similar to the human homologue. Three monoclonal antibodies against human DC-SIGN, AZN-D1, -D2 and -D3, cross-react with rhesus macaque DC-SIGN, whereas AZN-D2 does not cross-react with chimpanzee DC-SIGN. The primate homologues are abundantly expressed in lymphoid tissues such as lymph nodes, as well as in mucosal tissues involved in sexual transmission of HIV-1, and are functionally similar to human DC-SIGN. They have a high affinity for the immunological ligands of DC-SIGN: ICAM-2 and -3. Moreover, both homologues bind the HIV-1 envelope glycoprotein gp120 and therefore can act as a HIV-1 trans-receptor in the same way as human DC-SIGN. These data demonstrate that primate models are suitable to further dissect the role of DC-SIGN in the transmission and pathogenesis of infection with immunodeficiency viruses.


Subject(s)
Cell Adhesion Molecules , Lectins, C-Type , Lectins/immunology , Macaca mulatta/immunology , Membrane Glycoproteins , Pan troglodytes/immunology , Receptors, Cell Surface/immunology , Receptors, HIV/immunology , Simian Immunodeficiency Virus/immunology , Viral Envelope Proteins , Amino Acid Sequence , Animals , Antibodies, Monoclonal , Base Sequence , Cross Reactions , DNA, Complementary/genetics , Dendritic Cells/immunology , Gene Expression , HIV Envelope Protein gp120/immunology , HIV Infections/immunology , HIV-1/immunology , Humans , Lectins/genetics , Ligands , Macaca mulatta/genetics , Molecular Sequence Data , Pan troglodytes/genetics , Receptors, Cell Surface/genetics , Receptors, HIV/genetics , Sequence Homology, Amino Acid , Species Specificity
16.
Vaccine ; 20(3-4): 304-21, 2001 Nov 12.
Article in English | MEDLINE | ID: mdl-11672892

ABSTRACT

The severity of the AIDS epidemic clearly emphasises the urgent need to expedite HIV vaccine candidates into clinical trials. Prophylactic HIV vaccine candidates have been evaluated in non-human primates. Based on specific proof of principle studies the first phase III clinical studies have recently begun in humans. However, a truly effective HIV vaccine is not yet at hand and many problems related to specific properties of the virus remain to be overcome. Previously proven empirical approaches have largely failed and now rational thinking based on an understanding of immunity to lentiviral infections is needed. This review addresses the scientific problems and complications facing the development of an HIV vaccine as well as the possible strategies currently available to overcome these problems. Recent attention has focussed on identifying the immune correlates and mechanisms of protection from either HIV infection or protection from disease progression. Based on these observations, the logic and rational behind the development of multiple component vaccine strategies are highlighted.


Subject(s)
AIDS Vaccines/immunology , AIDS Vaccines/administration & dosage , Genetic Vectors , HIV/classification , Humans , Immunity, Mucosal , Vaccines, DNA/immunology , Vaccines, Synthetic/immunology
17.
Virology ; 287(1): 13-7, 2001 Aug 15.
Article in English | MEDLINE | ID: mdl-11504537

ABSTRACT

We obtained sealed vials of two different polio vaccine lots, expiration date 1955, which were used in the first U.S. polio vaccine campaign. These early lots were pulled from the market because they contained live infectious poliovirus which caused polio in some of the vaccines. Theoretically, these vaccines could have contained other infectious retroviruses, including HIV. No viral sequences were detected using RT-PCR analyses with primers capable of amplifying chimpanzee SIV and HIV-1-related viruses nor with primers for macaque SIV, sooty mangabey SIV, and HIV-2-related viruses. Poliovirus sequences were readily amplified by RT-PCR, suggesting that the technique used would have detected SIV or HIV sequences, if present.


Subject(s)
Drug Contamination , HIV/isolation & purification , Poliovirus Vaccines/chemistry , Simian Immunodeficiency Virus/isolation & purification , Animals , Cercocebus atys , HIV-1/isolation & purification , HIV-2/isolation & purification , Humans , Pan troglodytes , Reverse Transcriptase Polymerase Chain Reaction
18.
J Virol ; 75(17): 8137-46, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11483759

ABSTRACT

The nef genes of human immunodeficiency virus and simian immunodeficiency virus (SIV) overlap about 80% of the U3 region of the 3' long terminal repeat (LTR) and contain several essential cis-acting elements (here referred to as the TPI region): a T-rich region, the polypurine tract, and attachment (att) sequences required for integration. We inactivated the TPI region in the nef reading frame of the pathogenic SIVmac239 clone (239wt) by 13 silent point mutations. To restore viral infectivity, intact cis-regulatory elements were inserted just downstream of the mutated nef gene. The resulting SIV genome contains U3 regions that are 384 bp shorter than the 517-bp 239wt U3 region. Overall, elimination of the duplicated Nef coding sequences truncates the proviral genome by 350 bp. Nonetheless, it contains all known coding sequences and cis-acting elements. The TPI mutant virus expressed functional Nef and replicated like 239wt in all cell culture assays and in vivo in rhesus macaques. Notably, these SIVmac constructs allow us to study Nef function in the context of replication-competent viruses without the restrictions of overlapping LTR sequences and important cis-acting elements. The genomes of all known primate lentiviruses contain a large overlap between nef and the U3 region. We demonstrate that this conserved genomic organization is not obligatory for efficient viral replication and pathogenicity.


Subject(s)
Genes, nef , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/physiology , Simian Immunodeficiency Virus/pathogenicity , Terminal Repeat Sequences/genetics , Virus Replication , Animals , Cell Line , Gene Products, nef/metabolism , Macaca mulatta , Mutation , Polymerase Chain Reaction , Simian Immunodeficiency Virus/genetics , Transfection
19.
J Infect Dis ; 184(2): 136-43, 2001 Jul 15.
Article in English | MEDLINE | ID: mdl-11424009

ABSTRACT

Recent evidence suggests a much higher prevalence of human immunodeficiency virus type 1 (HIV-1) recombinants than previously anticipated. These recombinants arise from secondary HIV infections in individuals already infected with the virus. It remains unclear why some individuals acquire secondary HIV-1 infections and others do not. To address this question, a study was undertaken of a small cohort of chimpanzees with well-defined HIV-1 infection. After exposure to an infectious dose of heterologous primary isolate, 4 of 8 HIV-1 seropositive chimpanzees resisted secondary infection, whereas 2 naive controls became readily infected. Only animals who were immunologically boosted were protected. Protection from heterologous secondary exposure appeared to be related to the repertoire of the cytolytic CD8(+) T cell responses to HIV-1. Data suggested that immunologic boosting by HIV-1 antigens or exposure to subinfectious doses of virus may be important events in sustaining sufficient immunity to prevent secondary infections from occurring.


Subject(s)
AIDS Vaccines/administration & dosage , Acquired Immunodeficiency Syndrome/immunology , Acquired Immunodeficiency Syndrome/prevention & control , T-Lymphocytes, Cytotoxic/immunology , AIDS Vaccines/immunology , Animals , HIV Infections/immunology , Pan troglodytes
20.
Mol Biol Evol ; 18(4): 472-80, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11264398

ABSTRACT

Mitochondrial DNA control region sequences of orangutans (Pongo pygmaeus) from six different populations on the island of Borneo were determined and analyzed for evidence of regional diversity and were compared separately with orangutans from the island of Sumatra. Within the Bornean population, four distinct subpopulations were identified. Furthermore, the results of this study revealed marked divergence, supportive evidence of speciation between Sumatran and Bornean orangutans. This study demonstrates that, as an entire population, Bornean orangutans have not experienced a serious genetic bottleneck, which has been suggested as the cause of low diversity in humans and east African chimpanzees. Based on these new data, it is estimated that Bornean and Sumatran orangutans diverged approximately 1.1 MYA and that the four distinct Bornean populations diverged 860,000 years ago. These findings have important implications for management, breeding, and reintroduction practices in orangutan conservation efforts.


Subject(s)
Genetic Variation , Pongo pygmaeus/genetics , Animals , Borneo , DNA, Mitochondrial/analysis , DNA, Mitochondrial/genetics , Indonesia , Phylogeny , Polymerase Chain Reaction , Pongo pygmaeus/classification , Sequence Analysis, DNA , Software
SELECTION OF CITATIONS
SEARCH DETAIL
...